Skip to main content
Explore URMC

menu

Lymphoma/Leukemia (CLL/SLL): Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL

Research Question:
What is the safety and efficacy of a new investigational combination of drugs venetoclax in combination with Ublituximab and Umbralisib (TGR-1202)) that have not been tried before?

Basic Study Information

Purpose:
If you participate in this study, you will start treatment with 3 cycles (each cycle is 28 days) of the combination of TG-1101 (ublituximab) and TGR-1202. After completing those 3 cycles, you will be given 4 cycles of treatment with venetoclax and TGR-1202 at different doses to try to find the dose combination that may work the best. Depending on how your disease responds to treatment, you may then also receive up to 5 cycles of extended therapy with TGR-1202 alone.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03379051?term=venetoclax+in+combination+with+Ublituximab&rank=1
Study Reference #: ILYM17064

Lead Researcher (Principal Investigator)

Lead Researcher: Paul Barr

Study Contact Information

Study Coordinator: Andrew Bui
Phone: (585) 276-4405
Email: Andrew_bui@urmc.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Lymphoid leukemia, chronic

Return to Search